Noopept (Noopept (GVS-111))
A dipeptide-derived nootropic ~1000x more potent than piracetam. Enhances memory, focus, and provides neuroprotection through BDNF/NGF upregulation and AMPA/NMDA modulation.
How it works
Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement.
Key facts
- Molecular weight: 318.4 Da
- Half-life: 30-60 minutes (active metabolite longer)
- Bioavailability: High (oral/sublingual)
- Storage: Room temperature, dry, sealed.
Dosing overview
- Typical dose: 10-30 mg
- Frequency: 2-3x daily
- Duration: 4-8 weeks (cycle)
- Route: Oral or Sublingual
Reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
Possible side effects
- Headache
- Irritability
- Insomnia (if late)
- Restlessness
Research
- Noopept in mild cognitive impairment (2021): 20mg daily improved MMSE by 3 points and attention by 25% vs placebo over 8 weeks.
- Neuroprotective mechanisms of GVS-111 (2020): Reduced neuronal death by 50% under oxidative stress via HIF-1a stabilization.
Compare Noopept
Community discussions about Noopept
- My first week with Adamax + Noopept: focus, mood and a surprising headache - 4 comments
- My one-week Noopept trial – focus boost and a nagging headache - 7 comments
- Noopept + Adamax: My Low‑Dose Focus Experiment - 3 comments
- Noopept’s BDNF boost? Quick read and my take - 3 comments
- FDA May Loosen Peptide Rules, But Safety Still a Big Question - 8 comments
- Ask the community about Noopept
Research and educational reference only. Not medical advice.